Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 8/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 8/20 | 0.42 |
| ▸ | APP | P05067 | 8/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20120517 | 0.78 | SSTR4 (0.41) | KCNJ5KCNJ3APP | |
| SCHEMBL20129232 | 0.78 | KCNJ5 (0.41) | KCNJ5KCNJ3APP | |
| SCHEMBL20129078 | 0.78 | SSTR4 (0.41) | KCNJ5KCNJ3APP | |
| SCHEMBL18704558 | 0.77 | CNR2 (0.39) | PLAUMEN1KMT2A | |
| SCHEMBL11882534 | 0.74 | LMNA (0.53) | KCNJ5KCNJ3PLAUKDM4E | |
| SCHEMBL8875878 | 0.73 | THRB (0.42) | PLAUMAPT | |
| SCHEMBL30864859 | 0.73 | PLAU (0.40) | PLAUKDM4EMAPTMEN1KMT2A | |
| SCHEMBL29962623 | 0.73 | MEN1 (0.42) | APPMEN1KMT2A | |
| SCHEMBL21512638 | 0.72 | KDM4E (0.46) | KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11624600 | 0.72 | KCNJ5 (0.42) | KCNJ5KCNJ3APPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | KCNJ5 4683/4885KCNJ3 4669/4885APP 95/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | KCNJ5 4634/4885KCNJ3 4585/4885APP 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.